New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab)...

Related Keywords

Montreal ,Quebec ,Canada ,Spring House ,British Columbia ,United States ,Denmark ,Copenhagen ,Køavn ,Americans ,Waqqas Afif ,Jan Wehkamp ,Colitis Organization ,Division Of Experimental Medicine ,Crohn Colitis Foundation ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Department Of Medicine ,University Health Centre ,None Of The Janssen Pharmaceutical Companies ,Division Of Gastroenterology ,National Institutes Of Health ,Exchange Commission ,Companies Of Johnson ,Johnson ,Crohn Colitis Foundation Of America ,European Crohn ,Associate Professor ,Experimental Medicine ,Vice President ,Gastroenterology Disease Area Leader ,Janssen Research ,Global Assessment ,Reversible Encephalopathy Syndrome ,Prescribing Informationand Medication Guidefor ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Final Pooled Long Term Safety Analysis Through ,Ulcerative Colitis Through ,Final Clinical ,Endoscopy Outcomes ,Accessed February ,Ustekinumab Induction ,Maintenance Therapy ,Participants With Moderately ,Severely Active Ulcerative Colitis ,Colitis Foundation ,Facts About Inflammatory Bowel ,Janssen Pharmaceutical Companies Of Johnson Amp ,